Formoterol/fluticasone inhalation capsules - Sun Pharmaceutical Industires

Drug Profile

Formoterol/fluticasone inhalation capsules - Sun Pharmaceutical Industires

Alternative Names: Avessa

Latest Information Update: 30 Mar 2015

Price : $50

At a glance

  • Originator Ranbaxy Laboratories
  • Class Antiallergics; Antiasthmatics; Ethanolamines; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
  • 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top